Where to buy mavacamten

Mavacamten is a new first-in-class oral drug approved by the U.S. Food and Drug Administration (FDA) as an allosteric modulator of cardiac myosin ATPase for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM). This drug is currently indicated for the treatment of adults with symptomatic heart failure of New York Heart Association (NYHA) class II and III secondary to obstructive HCM and is designed to improve functional capacity and relieve symptoms.

HCM is a common genetic heart disease marked by left ventricular hypertrophy and caused by mutations in cardiac sarcomere-related genes, such as myosin-binding protein C and β-myosin heavy chain. Mavacate works by targeting the underlying myofibrillar disorder and abnormal mitral valve apparatus that lead to left ventricular outflow tract (LVOT) obstruction in HCM. MavacateAs a new drug in the treatment of patients with heart failure symptoms secondary to obstructive HCM, its indications, mechanism of action, adverse reactions and monitoring programs are particularly important.

With its launch in the domestic market, patients can purchase it through multiple channels. When the patient sees a doctor, the doctor will judge whether the drug is suitable for use based on the patient's condition and provide a prescription. With a prescription, patients can purchase it at the hospital pharmacy or pharmacy. If this drug cannot be purchased in domestic hospitals and other places, you can also purchase Mavaceta through relevant overseas channels. Since the drug is a capsule preparation and must be stored at a suitable temperature and humidity, when choosing a suitable channel, you need to consider whether its storage and transportation services for the drug meet the requirements. Therefore, patients need to ensure that they choose legal and safe channels when purchasing to ensure the effectiveness and safety of the medication.

Reference materials:https://www.ncbi.nlm.nih.gov/books/NBK582152/